The White House announced on September 18 that most-favored-nation drug pricing now extends to every state’s Medicaid program, bringing to government-funded coverage the same rebate structure manufacturers already apply to direct consumer drug purchases. Under the arrangement, called the GENEROUS Medicaid Payment Model, participating drugmakers agree that Medicaid will not pay more for a covered brand-name drug than the lowest price charged in other wealthy nations. The Council of Economic Advisers projects the expansion will save $64.3 billion over the next decade, split between the federal government and the states that jointly fund Medicaid.
The GENEROUS Model’s Rebate Mechanism
The GENEROUS Medicaid Payment Model works through rebates rather than mandated price caps. When a participating manufacturer’s brand-name drug is dispensed to a Medicaid patient, the company sends the state program a rebate large enough to bring the net price down to the most-favored-nation level already offered in other wealthy countries. The White House says the model already covers hundreds of individual drugs across major treatment categories, including oncology, diabetes care, and asthma, and that Medicaid programs have already distributed one million free prescriptions of the blood thinner Eliquis under the broader manufacturer agreements tied to the same pricing push.
The manufacturer side of the program has grown steadily since Pfizer signed the first agreement in the fall of 2025. As of the administration’s most recent count, 26 pharmaceutical manufacturers now have most-favored-nation deals covering 89 percent of the branded drug market, a group that expanded in August to include mid-sized companies such as Teva Pharmaceuticals, Sun Pharma, and CSL alongside the original set of major drugmakers. Several of the newer entrants also agreed to contribute raw pharmaceutical ingredients, including antibiotics and an anticonvulsant, to a federal stockpile intended to reduce reliance on foreign drug manufacturing.
Medicaid has required drug manufacturers to pay rebates since a 1990 federal law tied the program’s price to a company’s best price in the domestic commercial market. The GENEROUS model layers a second, international benchmark on top of that existing rule: a manufacturer must now also compare its Medicaid price against what it charges in other developed countries and rebate the difference whenever the foreign price is lower. That extra layer is what the White House credits for pushing total projected savings higher, though the administration has not published a breakdown showing how much of the $64.3 billion reflects the new international comparison specifically versus the pre-existing domestic rebate formula.
Many of the drug classes covered by the rebate deal disproportionately affect Medicaid’s older enrollees, including the dual-eligible seniors whose income qualifies them for both Medicaid and Medicare. For those beneficiaries, Medicaid often covers prescription costs that Medicare’s Part D program does not fully absorb, including certain diabetes medications, oncology drugs, and long-term asthma treatments named in the White House’s list of covered drug categories. A lower Medicaid price on those drugs does not necessarily change what an individual senior pays at the pharmacy counter, since cost-sharing for the lowest-income Medicaid enrollees is already minimal in most states, but it does reduce the amount state budgets must set aside to keep those drugs on their formularies.
Where the help is written down: The programs that lower Medicare costs each run on a different form and a different office, and no single notice lists them together. See the state cost-help packs in The Medicare Cost & Coverage Protection Kit.
A $64.3 Billion Estimate Split Between Washington and the States
The Council of Economic Advisers estimates that extending most-favored-nation pricing to all 50 states’ Medicaid programs will save $64.3 billion over the next decade, split into $36.6 billion for the federal government and $27.6 billion for state governments. That division follows Medicaid’s existing cost-sharing formula, under which Washington and the states divide most program expenses, including prescription drug spending, according to a federal matching rate that varies by state income levels. The White House frames the state share of the projected savings as capital that governors can redirect toward other Medicaid priorities, from provider payments to home-based care, without raising state taxes.
The Medicaid figure is a fraction of the $600 billion in savings the Council of Economic Advisers projects across the full most-favored-nation campaign over the same ten-year window, a broader total that also counts the direct-to-consumer discounts sold through the federal TrumpRx.gov portal. The two programs work differently: TrumpRx discounts require a patient to fill a prescription through that specific channel, while the Medicaid rebate is negotiated directly between the manufacturer and the state program and applies without a beneficiary taking any separate action. That distinction is why the administration is treating the Medicaid savings as a distinct, recurring budget line rather than folding it into its consumer-facing announcements.
The White House frames the state share of the savings as a lever governors can use without returning to their legislatures for new revenue, describing the freed-up money as capital states can redirect toward what the administration calls their most vulnerable residents. Because Medicaid is one of the largest line items in nearly every state budget, even a multibillion-dollar reduction in projected drug spending can ripple into decisions about provider payment rates, home- and community-based care waiting lists, and other services competing for the same pool of state dollars.
The Medicaid expansion is the latest step in a policy line that stretches back to May 12, 2025, when the president signed an executive order directing agencies to pursue most-favored-nation pricing across federal health programs. That order led to the first manufacturer agreement, with Pfizer, in the fall of 2025, followed by a steady cadence of additional deals roughly every one to two months through the summer of 2026, culminating in the announcement that Medicaid rebates now apply nationwide rather than in a subset of participating states.
TrumpRx.gov and the Consumer Side of the Same Pricing Deals
The most-favored-nation framework driving the Medicaid rebates is the same one already cutting prices for consumers who buy directly through TrumpRx.gov. Since that portal launched in February, the monthly price of Ozempic has fallen from $1,028 to an average of $350, and the injectable form of Wegovy is priced as low as $199 depending on dosage. Other discounted drugs on the site include inhalers for asthma and chronic obstructive pulmonary disease, insulin priced as low as $25 a month, and fertility medications that patients previously paid for almost entirely out of pocket.
The same pricing campaign also includes a narrower benefit aimed specifically at seniors: since July 2026, Medicare beneficiaries without existing coverage for GLP-1 weight-loss drugs have been able to access them for $50 a month through a separate arrangement tied to the manufacturer agreements. The White House says roughly 600,000 seniors used that option in its first two months, saving a combined $216 million on drugs that otherwise carry list prices well above $1,000 a month before any rebate or TrumpRx discount is applied.
The administration’s savings estimate is explicitly a projection, not a guarantee: the Council of Economic Advisers ties the $64.3 billion figure to a full decade of drug utilization and rebate compliance that has not yet played out. The White House has pointed to more immediate evidence that the underlying deals are active, noting that nine of the manufacturers that joined the most-favored-nation program in August alone committed to invest a combined $19.6 billion in U.S. pharmaceutical manufacturing, separate from the Medicaid rebates themselves. That investment commitment landed the same month those nine companies extended Medicaid rebate access nationwide, underscoring how directly the manufacturers’ side of the bargain is tied to the pricing changes now reaching every state’s program.
Drug Pricing Changes and the Bills That Follow
Most-favored-nation pricing changes what a state Medicaid program pays a manufacturer, but it does not touch the separate set of rules that govern an individual’s own Medicare Part D plan, including which drugs are on that plan’s formulary, when a prior authorization is required, and how much a beneficiary pays before reaching the plan’s out-of-pocket cap. Those plan-level rules shift every year regardless of what happens with federal drug-pricing deals, and they are the ones that determine what shows up on a specific person’s pharmacy receipt.
The Medicare Cost & Coverage Protection Kit is a 10-page kit that walks through the prior-authorization appeal steps and includes a medication and cost tracker for keeping plan rules and drug prices in one place.
Compare a Part D plan’s rules against the prior-authorization appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
